Squarepoint
FULC icon

Squarepoint’s Fulcrum Therapeutics FULC Stock Holding History

Squarepoint’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-57,900
Closed -$272K – 4865
2024
Q4 		$272K Hold
57,900
– – ﹤0.01% 4227
2024
Q3 		$207K Sell
57,900
-63,600
-52% -$472K ﹤0.01% 3670
2024
Q2 		$753K Buy
121,500
+101,400
+504% +$768K ﹤0.01% 2764
2024
Q1 		$190K Buy
+20,100
New +$179K ﹤0.01% 3629

Other funds holding FULC

Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Squarepoint's FULC Position: Q3 2026 in Review

Squarepoint reduced its Fulcrum Therapeutics (FULC) stake by 13% in Q3 2026, selling an estimated $62.3K and leaving 109,956 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #3534.

Squarepoint first reported a position in FULC in Q1 2020 and has held it in 16 quarters since. The position peaked at $1.35M in Q1 2026. 73 funds tracked by Wall St. Rank hold FULC as of Q3 2026.

  • Squarepoint held 109,956 shares of Fulcrum Therapeutics worth $407K as of Q3 2026.
  • Squarepoint sold 16,602 Fulcrum Therapeutics shares in Q3 2026, an estimated $62.3K.
  • Fulcrum Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #3534 holding.
  • Squarepoint first reported a position in Fulcrum Therapeutics in Q1 2020 and has held it in 16 quarters since.
  • Squarepoint's Fulcrum Therapeutics position peaked at $1.35M in Q1 2026.
  • 73 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.